Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ID: DRG0UHXQK)
| ADC Name |
SYS6041
|
|||||
|---|---|---|---|---|---|---|
| Synonyms |
SYS6041
Click to Show/Hide
|
|||||
| Organization |
CSPC Pharmaceutical Group (Originator)
|
|||||
| Drug Status |
Phase 1
|
|||||
| Drug-to-Antibody Ratio |
8
|
|||||
| Antibody Name |
Anti-FRα mAb
|
Antibody Info | ||||
| Antigen Name |
Folate receptor alpha (FOLR1)
|
Antigen Info | ||||
| Payload Name |
Exatecan
|
Payload Info | ||||
| Payload Target |
DNA topoisomerase 1 (TOP1)
|
Target Info | ||||
| Linker Name |
A cleavable linker
|
Linker Info | ||||
| Conjugate Type |
Undisclosed
|
|||||
2027 Update
The disease landscape of This ADC
2027 Update
The clinical trial pipelines of This ADC
2027 Update
ADC-specific functional property
Bystander Killing Effect
| Bystander Killing Effect | Description | Reference |
|---|---|---|
| yes |
SYS6041 demonstrated potent cytotoxicities against FRalpha expressing cancer cell-lines and effective bystander activities towards tumor cells without FRalpha expression.
|
[1]
|
References